Chemically and biologically synthesized CPP-modified gelonin for enhanced anti-tumor activity

Journal of Controlled Release

Volumn 172, Issue 1, 2013, Pages 169-178

  Shin, Meong Cheol ^a,b   Zhang, Jian ^a,b   David, Allan E ^c   Trommer, Wolfgang E ^d   Kwon, Young Min ^e   Min, Kyoung Ah ^b   Kim, Jin H ^b   Yang, Victor C ^a,b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF MICHIGAN   (United States)

^c AUBURN UNIVERSITY   (United States)

^d Rheinland Pfälzische Technische Universität Kaiserslautern Landau   (Germany)

^e NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

Cancer; Cell penetrating peptide; Gelonin; LMWP; Ribosome inactivating protein; Toxin

Indexed keywords

CANCER; CELL-PENETRATING PEPTIDE; GELONIN; LMWP; RIBOSOME-INACTIVATING PROTEIN; TOXIN;

CELL MEMBRANES; DISEASES; PEPTIDES; TUMORS;

CYTOLOGY;

GELONIN; PROTAMINE; RECOMBINANT PROTEIN;

ADENOCARCINOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONJUGATE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SYNTHESIS; GENETIC RECOMBINATION; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PURIFICATION; RAT; THERAPY EFFECT; TUMOR XENOGRAFT;

CANCER; CELL PENETRATING PEPTIDE; GELONIN; LMWP; RIBOSOME-INACTIVATING PROTEIN; TOXIN;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CELL-PENETRATING PEPTIDES; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASMS; RATS; RECOMBINANT FUSION PROTEINS; RIBOSOME INACTIVATING PROTEINS, TYPE 1; SUREGADA;

EID: 84883609896     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.08.016     Document Type: Article

References (49)

1. M.V. Blagosklonny The power of chemotherapeutic engineering: arresting cell cycle and suppressing senescence to protect from mitotic inhibitors Cell Cycle 10 2011 2295 2298
2. R.J. Kreitman Immunotoxins Expert. Opin. Pharmacother. 1 2000 1117 1129
3. G.R. Devi siRNA-based approaches in cancer therapy Cancer Gene Ther. 13 2006 819 829
4. G.P. Adams, and L.M. Weiner Monoclonal antibody therapy of cancer Nat. Biotechnol. 23 2005 1147 1157 (Pubitemid 41486396)
5. C. Foged, and H.M. Nielsen Cell-penetrating peptides for drug delivery across membrane barriers Expert Opin. Drug Deliv. 5 2008 105 117 (Pubitemid 351234112)
6. E.L. Snyder, and S.F. Dowdy Cell penetrating peptides in drug delivery Pharm. Res. 21 2004 389 393 (Pubitemid 38338971)
7. F. Stirpe On the action of ribosome-inactivating proteins: are plant ribosomes species-specific? Biochem. J. 202 1982 279 280
8. M. Puri, I. Kaur, M.A. Perugini, and R.C. Gupta Ribosome-inactivating proteins: current status and biomedical applications Drug Discov. Today 17 2012 774 783
9. F. Stirpe Ribosome-inactivating proteins Toxicon 44 2004 371 383 (Pubitemid 39070639)
10. N.E. Tumer, and X.P. Li Interaction of ricin and Shiga toxins with ribosomes Curr. Top. Microbiol. Immunol. 357 2012 1 18
11. F. Stirpe, S. Olsnes, and A. Pihl Gelonin, a new inhibitor of protein synthesis, nontoxic to intact cells. Isolation, characterization, and preparation of cytotoxic complexes with concanavalin A J. Biol. Chem. 255 1980 6947 6953 (Pubitemid 11234436)
12. S.F. Atkinson, T. Bettinger, L.W. Seymour, J.P. Behr, and C.M. Ward Conjugation of folate via gelonin carbohydrate residues retains ribosomal-inactivating properties of the toxin and permits targeting to folate receptor positive cells J. Biol. Chem. 276 2001 27930 27935
13. M. Yamaizumi, E. Mekada, T. Uchida, and Y. Okada One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell Cell 15 1978 245 250 (Pubitemid 9027527)
14. A.D. Frankel, and C.O. Pabo Cellular uptake of the tat protein from human immunodeficiency virus Cell 55 1988 1189 1193 (Pubitemid 19020071)
15. F. Heitz, M.C. Morris, and G. Divita Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics Br. J. Pharmacol. 157 2009 195 206
16. E. Koren, and V.P. Torchilin Cell-penetrating peptides: breaking through to the other side Trends Mol. Med. 18 2012 385 393
17. M. Magzoub, and A. Graslund Cell-penetrating peptides: [corrected] from inception to application Q. Rev. Biophys. 37 2004 147 195 (Pubitemid 40867965)
18. D. Derossi, S. Calvet, A. Trembleau, A. Brunissen, G. Chassaing, and A. Prochiantz Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent J. Biol. Chem. 271 1996 18188 18193 (Pubitemid 26250811)
19. Y.M. Kwon, Y.T. Li, J.F. Liang, Y.J. Park, L.C. Chang, and V.C. Yang PTD-modified ATTEMPTS system for enhanced asparaginase therapy: a proof-of-concept investigation J. Control. Release 130 2008 252 258
20. Y.J. Park, L.C. Chang, J.F. Liang, C. Moon, C.P. Chung, and V.C. Yang Nontoxic membrane translocation peptide from protamine, low molecular weight protamine (LMWP), for enhanced intracellular protein delivery: in vitro and in vivo study FASEB J. 19 2005 1555 1557 (Pubitemid 41279029)
21. J.K. Choi, J.H. Jang, W.H. Jang, J. Kim, I.H. Bae, J. Bae, Y.H. Park, B.J. Kim, K.M. Lim, and J.W. Park The effect of epidermal growth factor (EGF) conjugated with low-molecular-weight protamine (LMWP) on wound healing of the skin Biomaterials 33 2012 8579 8590
22. H. Xia, X. Gao, G. Gu, Z. Liu, N. Zeng, Q. Hu, Q. Song, L. Yao, Z. Pang, X. Jiang, J. Chen, and H. Chen Low molecular weight protamine-functionalized nanoparticles for drug delivery to the brain after intranasal administration Biomaterials 32 2011 9888 9898
23. Y.M. Kwon, H.S. Chung, C. Moon, J. Yockman, Y.J. Park, S.D. Gitlin, A.E. David, and V.C. Yang l-Asparaginase encapsulated intact erythrocytes for treatment of acute lymphoblastic leukemia (ALL) J. Control. Release 139 2009 182 189
24. Y.S. Park, Y. Huang, Y.J. Park, A.E. David, L. White, H. He, H.S. Chung, and V.C. Yang Specific down regulation of 3T3-L1 adipocyte differentiation by cell-permeable antisense HIF1alpha-oligonucleotide J. Control. Release 144 2010 82 90
25. L.C. Chang, H.F. Lee, Z. Yang, and V.C. Yang Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (I): preparation and characterization AAPS PharmSci 3 2001 E17
26. L.C. Chang, J.F. Liang, H.F. Lee, L.M. Lee, and V.C. Yang Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (II): in vitro evaluation of efficacy and toxicity AAPS PharmSci 3 2001 E18
27. L.M. Lee, L.C. Chang, S. Wrobleski, T.W. Wakefield, and V.C. Yang Low molecular weight protamine as nontoxic heparin/low molecular weight heparin antidote (III): preliminary in vivo evaluation of efficacy and toxicity using a canine model AAPS PharmSci 3 2001 E19
28. M. Hossann, Z. Li, Y. Shi, U. Kreilinger, J. Buttner, P.D. Vogel, J. Yuan, J.G. Wise, and W.E. Trommer Novel immunotoxin: a fusion protein consisting of gelonin and an acetylcholine receptor fragment as a potential immunotherapeutic agent for the treatment of Myasthenia gravis Protein Expr. Purif. 46 2006 73 84 (Pubitemid 43246998)
29. S.R. Urva, V.C. Yang, and J.P. Balthasar Physiologically based pharmacokinetic model for T84.66: a monoclonal anti-CEA antibody J. Pharm. Sci. 99 2010 1582 1600
30. S. Madan, and P.C. Ghosh Interaction of gelonin with macrophages: effect of lysosomotropic amines Exp. Cell Res. 198 1992 52 58
31. G. Saito, J.A. Swanson, and K.D. Lee Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities Adv. Drug Deliv. Rev. 55 2003 199 215 (Pubitemid 36135916)
32. A. Joliot, and A. Prochiantz Transduction peptides: from technology to physiology Nat. Cell Biol. 6 2004 189 196 (Pubitemid 38344356)
33. T.Y. Lee, Y.S. Park, G.A. Garcia, R.K. Sunahara, J.H. Woods, and V.C. Yang Cell permeable cocaine esterases constructed by chemical conjugation and genetic recombination Mol. Pharm. 9 2012 1361 1373
34. E. Vives, P. Brodin, and B. Lebleu A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus J. Biol. Chem. 272 1997 16010 16017 (Pubitemid 27265584)
35. A. van den Berg, and S.F. Dowdy Protein transduction domain delivery of therapeutic macromolecules Curr. Opin. Biotechnol. 22 2011 888 893
36. M. Mae, and U. Langel Cell-penetrating peptides as vectors for peptide, protein and oligonucleotide delivery Curr. Opin. Pharmacol. 6 2006 509 514 (Pubitemid 44340662)
37. J.M. Lambert, P.D. Senter, A. Yau-Young, W.A. Blattler, and V.S. Goldmacher Purified immunotoxins that are reactive with human lymphoid cells. Monoclonal antibodies conjugated to the ribosome-inactivating proteins gelonin and the pokeweed antiviral proteins J. Biol. Chem. 260 1985 12035 12041 (Pubitemid 16228361)
38. G.D. McIntyre, C.F. Scott Jr., J. Ritz, W.A. Blattler, and J.M. Lambert Preparation and characterization of interleukin-2-gelonin conjugates made using different cross-linking reagents Bioconjug. Chem. 5 1994 88 97 (Pubitemid 2043895)
39. R.R. Traut, A. Bollen, T.T. Sun, J.W. Hershey, J. Sundberg, and L.R. Pierce Methyl 4-mercaptobutyrimidate as a cleavable cross-linking reagent and its application to the Escherichia coli 30S ribosome Biochemistry 12 1973 3266 3273
40. G.L. Ellman Tissue sulfhydryl groups Arch. Biochem. Biophys. 82 1959 70 77
41. J.F. Kane Effects of rare codon clusters on high-level expression of heterologous proteins in Escherichia coli Curr. Opin. Biotechnol. 6 1995 494 500
42. E.R. LaVallie, E.A. DiBlasio-Smith, L.A. Collins-Racie, Z. Lu, and J.M. McCoy Thioredoxin and related proteins as multifunctional fusion tags for soluble expression in E. coli Methods Mol. Biol. 205 2003 119 140
43. S.M. Singh, and A.K. Panda Solubilization and refolding of bacterial inclusion body proteins J. Biosci. Bioeng. 99 2005 303 310 (Pubitemid 40740579)
44. R.F. Ebert, and L.A. Spryn Immunotoxin construction with a ribosome-inactivating protein from barley Bioconjug. Chem. 1 1990 331 336
45. M.G. Battelli, L. Barbieri, and F. Stirpe Toxicity of, and histological lesions caused by, ribosome-inactivating proteins, their IgG-conjugates, and their homopolymers APMIS 98 1990 585 593 (Pubitemid 20255566)
46. M.V. Hosur, B. Nair, P. Satyamurthy, S. Misquith, A. Surolia, and K.K. Kannan X-ray structure of gelonin at 1.8 A resolution J. Mol. Biol. 250 1995 368 380
47. K. Mujoo, L. Cheung, J.L. Murray, and M.G. Rosenblum Pharmacokinetics, tissue distribution, and in vivo antitumor effects of the antimelanoma immunotoxin ZME-gelonin Cancer Immunol. Immunother. 40 1995 339 345
48. Z. Li, Y. Qu, H. Li, and J. Yuan Truncations of gelonin lead to a reduction in its cytotoxicity Toxicology 231 2007 129 136 (Pubitemid 46283156)
49. E. Goncalves, E. Kitas, and J. Seelig Binding of oligoarginine to membrane lipids and heparan sulfate: structural and thermodynamic characterization of a cell-penetrating peptide Biochemistry 44 2005 2692 2702 (Pubitemid 40279574)